Roxadustat not checked
Kyntra Bio · FG-4592 · ASP1517
FollowEvery change as it happens, and a Monday email
Trials
2 active
18 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Roxadustat will be administered per schedule specified in the arm description.”In the company’s words, NCT07722988 on ClinicalTrials.gov
- Tested for
- Myelodysplastic Syndromes
- Main trialPhase 3
- “The study is designed to determine the efficacy and safety of roxadustat for the treatment of anemia due to very low, low, or intermediate risk MDS in participants with high transfusion burden (HTB).”In the company’s words, NCT07722988 on ClinicalTrials.gov
- Other names
- FG-4592 · ASP1517 · AZD9941
Other drugs for Myelodysplastic Syndromes
- NTQ5082Nanjing Chia-tai Tianqing Pharmaceutical · Phase 3
- MY008211AWuhan Createrna Science and Technology Co., Ltd · Phase 3
- CrovalimabRoche · Phase 3
- DanicopanAlexion Pharmaceuticals, Inc. · Phase 3
- MomelotinibSierra Oncology LLC - a GSK company · Phase 2/3
- VenetoclaxAbbVie · Phase 3
Coming up1
- Sep 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials18
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Sep 2030 | A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS) | |
| Phase 4Completed | 19 Nov 2021 | Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney Disease | |
| Phase 3Completed | 19 Sep 2018 | Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis | |
| Phase 3Completed | 21 Sep 2018 | Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants | |
| Phase 3Completed | 24 Sep 2018 | A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis | |
| Phase 3Completed | 30 Jun 2021 | Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants | |
| Phase 3Completed | 9 Jul 2021 | Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants | |
| Phase 3Withdrawn | 23 May 2022 | Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD | |
| Phase 3Terminated | 9 Mar 2023 | Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden | |
| Phase 3Completed | 3 Apr 2023 | A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies | |
| Phase 2/3Completed | 11 Jan 2023 | Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS) | |
| Phase 2Completed | 21 Jun 2010 | Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis | |
| Phase 2Completed | 13 Jun 2012 | Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia | |
| Phase 2Completed | 15 Oct 2012 | Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis | |
| Phase 2Completed | 10 Jan 2013 | Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment | |
| Phase 2Completed | 12 Dec 2019 | Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease | |
| Phase 2Completed | 26 Mar 2021 | Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia | |
| Phase 4Authorised | not given | Effect of Roxadustat on Cardiometabolism |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026